- Report
- January 2025
- 250 Pages
Global
From €4752EUR$4,999USD£3,992GBP
- Report
- March 2025
- 283 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 92 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2024
- 92 Pages
Europe
From €1426EUR$1,500USD£1,198GBP
- Report
- October 2023
- 182 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- February 2024
- 180 Pages
Global
From €4724EUR$4,969USD£3,968GBP
- Report
- October 2023
- 82 Pages
United States
From €3327EUR$3,500USD£2,795GBP
- Report
- August 2023
- 220 Pages
Global
€4368EUR$4,595USD£3,670GBP
- Report
- January 2024
- 262 Pages
Global
€4749EUR$4,995USD£3,989GBP
- Report
- February 2023
- 817 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- May 2023
- 89 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Book
- April 2019
- 191 Pages
- Book
- April 2024
- 1280 Pages
- Book
- May 2016
- 512 Pages
- Book
- February 2015
- 288 Pages
- Book
- April 2014
- 744 Pages
- Book
- April 2013
- 412 Pages
- Book
- March 2009
- 278 Pages

The Cognitive Impairment market within the context of Neurology is a rapidly growing field of research and development. Cognitive Impairment is a broad term that encompasses a range of neurological conditions, including Alzheimer's Disease, Parkinson's Disease, and other forms of dementia. These conditions can cause a range of symptoms, including memory loss, difficulty with language, and difficulty with problem-solving. As the population ages, the prevalence of these conditions is expected to increase, creating a need for treatments and therapies.
The Cognitive Impairment market is highly competitive, with a range of companies offering products and services to address the needs of those affected by these conditions. Companies in this market include pharmaceutical companies, medical device manufacturers, and biotechnology companies. These companies are developing treatments and therapies to improve the quality of life for those affected by Cognitive Impairment. Examples of companies in this market include AbbVie, Biogen, and Novartis. Show Less Read more